Biomiga Diagnostics appointed Kevin Wang to lead the mobile platform integration with POCTs

Jan. 2, 2012 - PRLog -- Fountain Valley, CA – Biomiga Diagnostics, maker of Quantitative Point-of-Care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced the appointment of Kevin Wang to Director of IT and the launch of its website (www.biomigadiagnostics.com)  aiming at improving awareness of Therapeutic Drug Monitoring (TDM) in personalized medicine.  TDM point of care tests have the potential of revolutionize healthcare by allowing for the correct dosing across all therapeutic classes.  In some cases, dosing by fix dose, even when adjusted for body surface area, resulted in more than 50% of the patients either underdosed or overdosed.

Kevin has extensive experience at website design as well as mobile application design.  He obtained his MS in Computer Science from CSU at Sacramento and was Firmware Engineer at Intel.  As part of his philanthropic activity, he is currently the webmaster for Tzu Chi Foundation at San Diego Service Center―a nonprofit organization that he has been supporting for many years.  

“We are looking forward to working with Kevin to make personalized medicine a reality.  He will be leading our efforts to improve healthcare delivery by utilizing mobile technology in order to make clinical tests readily available anywhere at any time around the globe.” said Dr. Larn Hwang, Chief Operation Officer of Biomiga Diagnostics. “Kevin is a highly creative individual and no doubt will make tremendous progress in this coupling of mobile technology and point-of-care testing.”

About Biomiga Diagnostics

Biomiga Diagnostics’ mission is to transform healthcare by quantitative lateral flow tests for Therapeutic Drug Monitoring and biomarker testing.  These tests are simple to use and require no specialized equipment or trained personnel.  They are rapid with results within 20 minutes of blood collection.  They are convenient and can be deployed at home, in doctor’s office, in emergency room, or in centralized laboratory. Moreover, they are quantitative with linear response range similar to tests performed at centralized laboratories.  These proprietary diagnostic devices deployed at point-of-care are the solution to personalized healthcare allowing the dosing of the right patient with the right drug at the right dose.  Biomiga Diagnostics is currently offering two product suites to support the medical community:  1) The Emergency Care suite which includes cardiac biomarkers for heart attack (TnI, CKMB, Myoglobin) and heart failure (BNP). These are the most frequently ordered tests in the emergency rooms. 2) The Reproductive Biology suite which includes the gonadotropins (hCG, LH, FSH). The gonadotropins are widely used in assisted reproduction and their monitoring could improve treatment.  A Chemotherapy Dosing suite including Prostate specific antigen (PSA) is under development.

The executives of Biomiga Diagnostics are a group of pharmaceutical veterans who believe that the next revolution in medicine is in point-of-care tests for optimal drug dosing.  With more than a decade of drug development experience each, the leadership team has expertise ranging from basic/applied research, preclinical/clinical development, pharmacokinetics/pharmacodynamics biomarker development, mobile technology, regulatory, legal, marketing and business development.

http://www.biomigadiagnostics.com

Contact:
Larn Hwang PhD
Chief Operation Officer
lhwang@biomigadiagnostics.com

# # #

Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine,